No Data
Deep * company * beijing balance medical technology co., ltd. (688198): stable growth on the revenue side, bullish on the future performance increment of new products.
The company released the third quarter report for 2024, realizing a year-on-year revenue growth of 13.57% in the first three quarters of 2024, while the net income attributable to shareholders decreased by 16.56% year-on-year, putting pressure on the profit end. The company continues to increase its research and development investment.
Bairen Healthcare Third Quarter Report 2024
beijing balance medical technology co., ltd. (688198.SH): The net income in the first three quarters was 58.6934 million yuan, a year-on-year decrease of 16.56%.
On October 29, beijing balance medical technology co., ltd. (688198.SH) announced that in the first three quarters of 2024, it achieved total operating income of 0.292 billion yuan, a year-on-year increase of 13.57%; net income attributable to shareholders of the parent company decreased by 16.56% to 58.6934 million yuan; and the basic earnings per share was 0.43 yuan.
Express News | beijing balance medical technology co., ltd.: Collagen fiber filler - I registration application accepted.
Has the source of funds for the controlling shareholder's shareholding changed? Beijing Balance Medical Technology Co., Ltd. insider: Self-financing can also be done through "special shareholding loans".
①Company insiders have expressed that beijing balance medical technology co., ltd. plans to increase its shareholding through self-raised funds, not ruling out the possibility of increasing company stocks through bank's "stock shareholding special loans". ②Jin Lei, the director of beijing balance medical technology co., ltd., believes that against the backdrop of a sluggish performance in the medical instruments sector, the company's stock price is undervalued by the market.
Chinese Stocks Keeps Rally After Week-Long Holiday; Yuneng Technology Jumps 20%
No Data
No Data